Yale Journal of Health Policy, Law & Ethics, Vol. 11, Winter 2011
71 Pages Posted: 7 Dec 2010 Last revised: 16 Apr 2013
Date Written: November 29, 2010
The world faces a worsening public health crisis: A growing number of bacteria are resistant to available antibiotics. Yet there are few new antibiotics in the development pipeline to take the place of these increasingly ineffective drugs. We review a number of proposals intended to bolster drug development, including such financial incentives for pharmaceutical manufacturers as extending the effective patent life for new antibiotics. However, such strategies directly conflict with the clear need to reduce unnecessary antibiotic prescriptions and could actually increase prescription use. As an alternative, we recommend a two-prong, “integrated” strategy based on prizes administered through the insurance reimbursement system, but conditioned on the companies meeting conservation targets.
Keywords: antibiotic, resistance, intellectual property, patent, conservation, prize
JEL Classification: H41, H51, I18, K11, K19, K32, K33
Suggested Citation: Suggested Citation
Kesselheim, Aaron S. and Outterson, Kevin, Improving Antibiotic Markets for Long Term Sustainability (November 29, 2010). Yale Journal of Health Policy, Law & Ethics, Vol. 11, Winter 2011; Boston Univ. School of Law Working Paper (Law & Economics) No. 10-42; Boston Univ. School of Law Working Paper (Public Law & Legal Theory) No. 10-42. Available at SSRN: https://ssrn.com/abstract=1716942